Open AccessIID572: A New Potentially Best-In-Class β-Lactamase Inhibitor
Author(s) -
Folkert Reck,
Alun Bermingham,
Johanne Blais,
Anthony Casarez,
Richard A. Colvin,
Charles R. Dean,
Markus Furegati,
L Gamboa,
Ellena Growcott,
Cindy Li,
Sara López,
Louis E. Metzger,
Sandro Nocito,
Flavio Ossola,
Kaci Phizackerley,
Dita Rasper,
Jacob Shaul,
Xiaoyu Shen,
Robert L. Simmons,
Dazhi Tang,
Kyuto Tashiro,
Yue Qin
Publication year - 2019
Publication title -
acs infectious diseases
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 1.324
H-Index - 39
ISSN - 2373-8227
DOI - 10.1021/acsinfecdis.9b00031
Subject(s) - piperacillin/tazobactam , piperacillin , tazobactam , broad spectrum , microbiology and biotechnology , bacteria , dosing , biology , antibiotics , pharmacology , chemistry , genetics , combinatorial chemistry , pseudomonas aeruginosa
Resistance in Gram-negative bacteria to β-lactam drugs is mediated primarily by the expression of β-lactamases, and co-dosing of β-lactams with a β-lactamase inhibitor (BLI) is a clinically proven strategy to address resistance. New β-lactamases that are not impacted by existing BLIs are spreading and creating the need for development of novel broader spectrum BLIs. IID572 is a novel broad spectrum BLI of the diazabicyclooctane (DBO) class that is able to restore the antibacterial activity of piperacillin against piperacillin/tazobactam-resistant clinical isolates. IID572 is differentiated from other DBOs by its broad inhibition of β-lactamases and the lack of intrinsic antibacterial activity.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom